Remo CRO

News

Karyopharm Reports Positive Top-Line Phase 2b SADAL Data for Selinexor in Patients with Diffuse Large B-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting

12.04 2018.

NEWTON, Mass, Dec. 01, 2018 (GLOBE NEWSWIRE) — Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported positive top-line results from the Phase 2b SADAL (Selinexor Against Diffuse Aggressive Lymphoma)… Details

X4 Pharmaceuticals Presents Additional Positive Phase 2 Results for X4P 001 in WHIM Syndrome, Continues on Path to Initiation of Phase 3 Trial

12.04 2018.

CAMBRIDGE, MA – December 1, 2018 – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 allosteric antagonist drugs to improve immune cell trafficking to treat rare diseases and cancer, today announced the… Details

Novartis Announces New Crizanlizumab (SEG101) Data Analysis in Sickle Cell Disease, and Investment in SENTRY Clinical Program

12.04 2018.

Basel, December 1, 2018 – New data from a post hoc analysis of the Phase II SUSTAIN study of crizanlizumab — a once-a-month, humanized anti-P-selectin monoclonal antibody infusion being investigated for the treatment of sickle cell disease (SCD) –… Details

Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018

12.04 2018.

SUMMIT, N.J. & CAMBRIDGE, Mass.–(BUSINESS WIRE)– December 01, 2018 Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a pivotal, phase 3 trial (BELIEVE) evaluating the safety and efficacy… Details

Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia

12.01 2018.

DUBLIN, Nov. 29, 2018 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced positive topline results from ENLIGHTEN-2, a pivotal phase 3 study of ALKS 3831 (olanzapine/samidorphan), an investigational, novel, once-daily, oral atypical… Details

Pulmatrix Announces Positive Final Results from the Phase 1/1b Clinical Trial of Pulmazole – an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole

11.27 2018.

LEXINGTON, Mass., Nov. 21, 2018 /PRNewswire/ — Pulmatrix, Inc. (NASDAQ: PULM) announced the results of the completed first-in-human study of Pulmazole (PUR1900) — an inhaled iSPERSETM formulation of the anti-fungal drug itraconazole for the… Details